In spite of a major raise in price target to $110 by Credit Suisse. GILD, of course, was supposed to have a major competitor to ibrutinib in idelalasib, and I believe their ASH presentation was today. Nevertheless, a great company. Couldn't resist adding some here at 70.50. Looks like they're going to a bitrge PCYC @120 for a while. Precisely what happened with SNTS: locked at 23.75 until the buyout by Salix @ 32 was announced. A little cynicism is called for in this market.